Effect of Enhanced Recovery After Surgery (ERAS) on C-reactive and Visceral Proteins
NCT ID: NCT02348229
Last Updated: 2015-01-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
149 participants
INTERVENTIONAL
2013-09-30
2014-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Enhanced Recovery After Surgery (ERAS) in Gastric Cancer Surgery
NCT06209983
Enhanced Recovery After Surgery(ERAS) for Gastric Cancer and Perioperative Nutritional Status
NCT03043183
Prehabilitation Plus ERAS in Gastric Cancer Surgery
NCT07328633
ERAS for Gastric Cancer Patients After NACT
NCT06365814
Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center Study
NCT03121729
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ERAS group
ERAS protocols
ERAS protocols
Normal meal allowed until 6 h before surgery and Carbohydrate drink until 2 h before surgery
ERAS protocols
No bowel preparation
ERAS protocols
No nasogastric placement; if used, remove on the 1st postoperative day
ERAS protocols
Vasoactive drugs used if need be
ERAS protocols
Temperature management
ERAS protocols
Intra-abdominal drains not to be used
ERAS protocols
Intraperitoneal Ropivicaine infusion
ERAS protocols
On the 1st postoperative day Nasogastric catheter removed /Urinary catheter removed.
Oral non-opioid analgesia/Drinking 0.5L liquid. Active mobilisation
ERAS protocols
On the 2nd postoperative day：Drains removed Oral diet was initiated
ERAS protocols
3-4th postoperative day： Stop oral non opioid analgesia
ERAS protocols
On the5-6th postoperative day Check discharge criteria
conventional pathway group
using conventional pathway
conventional pathway group
No solid foods at dinner before surgery and no liquids 12 h before surgery. Routine bowel preparation Nasogastric placement on the morning of surgery
conventional pathway group
Routine use of anesthesia medicine. Standard 5-trocar laparoscopy-assisted procedure. I.V. fluids not restricted (Ringer's lactate 20 ml/kg in the first hour, then at the rate of 10-12 ml/kg/h) Routine use of abdominal drainage tubes and placement of catheters.
conventional pathway group
1st postoperative day: Keep Nasogastric catheter Removal of urinary catheter Opioid analgesic by intramuscular injection Parenteral nutrition until flatus. I.V. fluids not restricted Mobilization in bed
conventional pathway group
2nd postoperative day Patient is advised to get out of bed until 24-48h after surgery
conventional pathway group
3-4th postoperative day： Remove nasogastric tube after flatus Oral liquids started. Encouraged to walk in the ward.
conventional pathway group
5-6th postoperative day：Oral diet was changed from liquids to semi-fluids and normal food.
Drains removed
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ERAS protocols
Normal meal allowed until 6 h before surgery and Carbohydrate drink until 2 h before surgery
ERAS protocols
No bowel preparation
ERAS protocols
No nasogastric placement; if used, remove on the 1st postoperative day
ERAS protocols
Vasoactive drugs used if need be
ERAS protocols
Temperature management
ERAS protocols
Intra-abdominal drains not to be used
ERAS protocols
Intraperitoneal Ropivicaine infusion
ERAS protocols
On the 1st postoperative day Nasogastric catheter removed /Urinary catheter removed.
Oral non-opioid analgesia/Drinking 0.5L liquid. Active mobilisation
ERAS protocols
On the 2nd postoperative day：Drains removed Oral diet was initiated
ERAS protocols
3-4th postoperative day： Stop oral non opioid analgesia
ERAS protocols
On the5-6th postoperative day Check discharge criteria
conventional pathway group
No solid foods at dinner before surgery and no liquids 12 h before surgery. Routine bowel preparation Nasogastric placement on the morning of surgery
conventional pathway group
Routine use of anesthesia medicine. Standard 5-trocar laparoscopy-assisted procedure. I.V. fluids not restricted (Ringer's lactate 20 ml/kg in the first hour, then at the rate of 10-12 ml/kg/h) Routine use of abdominal drainage tubes and placement of catheters.
conventional pathway group
1st postoperative day: Keep Nasogastric catheter Removal of urinary catheter Opioid analgesic by intramuscular injection Parenteral nutrition until flatus. I.V. fluids not restricted Mobilization in bed
conventional pathway group
2nd postoperative day Patient is advised to get out of bed until 24-48h after surgery
conventional pathway group
3-4th postoperative day： Remove nasogastric tube after flatus Oral liquids started. Encouraged to walk in the ward.
conventional pathway group
5-6th postoperative day：Oral diet was changed from liquids to semi-fluids and normal food.
Drains removed
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosis confirmed by the endoscopic biopsy and total-body CT scan
3. No history of the chronic renal disease ,chronic liver disease, cardiopulmonary dysfunction, ASA score≦3
4. No neoadjuvant chemotherapy and radiotherapy
5. No digestive obstruction and distant metastasis
Exclusion Criteria
2. A large amount of bleeding leading(\>500ml)
3. Patients withdrew their consent
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The First Hospital of Jilin University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Quan Wang, Doctor
Role: STUDY_DIRECTOR
The First Hospital of Jilin University
References
Explore related publications, articles, or registry entries linked to this study.
Mingjie X, Luyao Z, Ze T, YinQuan Z, Quan W. Laparoscopic Radical Gastrectomy for Resectable Advanced Gastric Cancer Within Enhanced Recovery Programs: A Prospective Randomized Controlled Trial. J Laparoendosc Adv Surg Tech A. 2017 Sep;27(9):959-964. doi: 10.1089/lap.2016.0057. Epub 2016 Nov 22.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-212
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.